COMPUMEDICS LIMITED — Capital/Financing Update 2009

Jul 20, 2009

==> picture [76 x 80] intentionally omitted <==

ASX / MEDIA RELEASE

Compumedics Limited Preliminary 30 June 2009 business update:

Strong financial gains continue – new growth platforms in place and positioned for future sales growth

Melbourne Australia, Tuesday 21 July, 2009

Leading medical devices company, Compumedics Limited (ASX:CMP) today announced it would post a further significant improvement in the financial performance of its businesses for the year ended 30 June 2009 when it releases its preliminary audited results later in August. Whilst these results are still subject to audit, the key points to note are:

• The Company expects to report record net profit after-tax earnings for the year ended 30 June 2009 in excess of $2.4m.

• The Company has maintained sales for its existing core diagnostic capital equipment businesses during an incredibly difficult trading environment.

• The Company expects to report record cash generation for the financial year ended 30 June 2009.

• The Company has shipped its first SomniLink® SPAP® sleep-treatment devices to Europe.

• The Company expects to report its highest cash balances for the 30 June yearend in 4 years and has continued to reduce its bank debt, down a further 20% on a year ago to about $2.4m.

Compumedics has maintained its core business in a very difficult economic environment whilst strengthening its financial performance and also building the future growth platforms of the business.

A key growth platform that will underpin the profitable expansion of the Company’s core diagnostic business is:

• Compumedics Long-Term Monitoring (LTM) EEG device - Neuvo®, which will undergo global market rollouts over the next 12 months. This new device allows Compumedics to compete in a new global market estimated at approximately $0.5bn pa.

While the global economy is in a state of uncertainty forward guidance will be heeded with caution at least until markets return to some level of stability.

Compumedics Limited (ASX:CMP)

Released on 21 July, 2009 Page 1 of 2

Compumedics’ growth trajectory incorporates these significant milestones.

• Tripling of revenue over 10 years to over $37 million from $9 million in 1999.

• Listing on the ASX in 2000 and integrating two businesses in 2002 and 2004 to develop a company with world-class product with the discipline and systems to improve profitability by at least $7.1m post-acquisition and re-structuring.

• Establishing a unique presence covering the range of sleep markets for:

• diagnostics capital equipment, including conventional sleep labs and the emerging home-sleep testing, a $1+ billion market;

• services for operating sleep diagnostics labs, a $1+ billion market,

• treatment with the new generation SomniLink® SPAP® system a $2+ billion market.

• Establishing brain monitoring markets for short-term EEG monitoring, and now the $1 billion clinical long-term EEG.

• Establishing and developing market leadership in the $1 billion ultrasound monitoring market.

Compumedics will provide further up-dates as the financial results for the year ended 30 June 2009 are finalised and audited. The Company will make additional announcements in relation to the growth platforms as material milestones are achieved.

For Further information:

Mr David Burton Mr David Lawson Executive Chairman, CEO Chief Financial Officer Phone: + 61 3 8420 7300 Phone: + 61 3 8420 7300 Fax: +61 3 8420 7399 Fax: +61 3 8420 7399

Investor Relations & Media Enquires:

Mr Rod North Executive Director Bourse Communications Pty Ltd Phone: +61 3 9510 8309 Mobile: +61 (0) 408 670 706

About Compumedics

Compumedics Limited, founded in 1987, is a global leader in the design and manufacture of diagnostic technologies for sleep disorders, neurophysiology and cardiology. In 1987 Compumedics established Asia Pacific’s first fully computerised sleep laboratory. Compumedics holds 80% share of the Australian sleep-diagnostic market, and has a major and rapidly growing presence in the US, European and Asian marketplaces for its sleep, neurological, and Doppler blood-flow diagnostic monitoring devices. In 1995 the company was selected to supply equipment to the US Sleep Heart Health Study, the world’s largest sleep study of its kind, currently exceeding 14,000 studies with 20,000 patients scheduled by 2008. With headquarters in Melbourne, Australia and offices in the United States, and Europe the products are distributed in over 50 countries. In 1998 Compumedics was awarded the overall Australian Exporter of the Year. In 2000 Compumedics was listed on the Australian Stock Exchange. In 2002 , Compumedics - acquired US-based Neuroscan - the world's leading supplier of instruments for brain-research. In the US the world's largest medical device market - Neuroscan holds around 90% of the market for brain-research products. In 2003 Compumedics was awarded the Frost & Sullivan Award for Market Expansion Strategy. In 2004 , Compumedics acquired German-based DWL Elektronishe GmbH, enabling Compumedics to expand its global operations into the neurovascular and cardio-vascular diagnostic fields. In 2006 , Compumedics was awarded the Frost and Sullivan Technology Leadership award for the innovative Somté recorder product. In 2007 , Compumedics and Chairman were inducted into the Victorian Manufacturing Hall of Fame. In 2008 the DWL division received the top 100 German Innovation award. With 20,000 systems installed globally across the finest hospital, universities and clinics the Compumedics sales have grown more than 4 fold from $9 million (1999) to $39 million (2008). In 2009 Compumedics received an award for design excellence for its new generation Grael[TM] sleep diagnostic system. www.compumedics.com

Compumedics Limited (ASX:CMP)

Released on 21 July, 2009 Page 2 of 2